Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc Ord (OP:AZNCF)

183.00 +2.25 (+1.24%)
Streaming Delayed Price Updated: 3:25 PM EST, Dec 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc Ord

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
AstraZeneca's COVID-19 Antibody Provides Protection For At Least Six Months In High-Risk Individuals ↗
 
Via Benzinga
News headline image
UK-Based Start-Up Working On Next COVID-19 Vaccine Using Animal Feces: FT ↗
 
Via Benzinga
News headline image
Daiichi Sankyo - AstraZeneca's Enhertu Receives Priority Review In US For Lung Cancer ↗
 
Via Benzinga
News headline image
After Encouraging Data, Blueprint Medicines Plans Combination Cohort In Tagrisso Resistant Lung Cancer ↗
Blueprint Medicines Corp (NASDAQ: BPMC)  
Via Benzinga
News headline image
AstraZeneca Bets $25M On Preclinical Bispecific Antibody ↗
 
Via Benzinga
News headline image
AstraZeneca's Imfinzi Flunks In Late-Stage Advanced Cervical Cancer Study ↗
 
Via Benzinga
News headline image
Seagen Wins $42M Patent Claim Against Daiichi In Cancer Drug Case ↗
A jury in Marshall, Texas, awarded Seagen Inc (NASDAQ: SGEN)  
Via Benzinga
News headline image
FDA Official Says Frequent COVID-19 Booster Shows Not Sustainable: WSJ ↗
According to a U.S. health regulator, asking people to get COVID-19 boosters frequently wasn't sustainable because of vaccine fatigue, and authorities needed to develop a long-term strategy for... 
Via Benzinga
News headline image
AstraZeneca's Ultomiris Shows Sustained Improvements In Functional Activities In Neuromuscular Disease ↗
 
Via Benzinga
News headline image
Ionis Pharma - AstraZeneca Antisense Medicine Met Its Primary, Secondary Goals To Lower Cholesterol ↗
Ionis Pharmaceuticals Inc (NASDAQ: IONS) and its partner, AstraZeneca Plc (NASDAQ: AZN), have  
Via Benzinga
News headline image
EMA Recommends Approval Of AstraZeneca's COVID-19 Therapy, Evusheld ↗
EMA's human medicines committee (CHMP) has  
Via Benzinga
News headline image
AstraZeneca's COVID-19 Vaccine Expected To Win European Approval This Week: Reuters ↗
European Medicines Agency is expected to approve AstraZeneca Plc's (NASDAQ: AZN) antibody-based COVID-19 vaccine for preventing COVID-19 infections,  
Via Benzinga
News headline image
Bristol Myers Sues AstraZeneca Over PD-L1 Cancer Drug Patents ↗
Bristol Myers Squibb Co (NYSE: BMY) claims that AstraZeneca Plc's (NASDAQ: AZN) PD-L1 inhibitor, Imfinzi, infringed on at least eight patents in a newly filed complaint. 
Via Benzinga
News headline image
AstraZeneca's COVID-19 Antibody Neutralizes Omicron Sub-variants, Lab Study Shows ↗
AstraZeneca Plc's (NASDAQ: AZN) antibody-based cocktail to prevent and treat COVID-19 retained  
Via Benzinga
News headline image
AstraZeneca Mulls Ditching US Approval For Its COVID-19 Vaccine: FT ↗
Citing AstraZeneca Plc's (NASDAQ: AZN) head of research and development, the Financial Times reported that the Company  
Via Benzinga
News headline image
AstraZeneca Settles Ultomiris-Related Patent Litigation With Chugai ↗
Alexion Pharmaceuticals, a unit of AstraZeneca plc (NASDAQ: AZN), has entered into a settlement agreement with Chugai Pharmaceutical Co Ltd, resolving all patent disputes related to Ultomiris... 
Via Benzinga
News headline image
AstraZeneca's COVID-19 Therapy Approved In Britain As Preventive Option ↗
Britain's Medicines and Healthcare products Regulatory Agency (MHRA)  
Via Benzinga
News headline image
Europe Kickstarts Reviewing AstraZeneca Application For Its COVID Antibody ↗
 
Via Benzinga
News headline image
White House Warns It Cannot Afford COVID-19 Related Solutions If Cases Increase: FT ↗
The White House says that the U.S. is running out of money to pay for COVID-19 vaccines, tests, and treatments, making it unprepared for any rising cases in the future. 
Via Benzinga
News headline image
Merck-AstraZeneca Stop Keytruda/Lynparza Combo Trial In Prostate Cancer Patients ↗
Merck & Co Inc (NYSE: MRK) will stop the Phase 3 KEYLYNK-010 trial investigating Keytruda combined with Lynparza for metastatic castration-resistant prostate cancer (mCRPC). 
Via Benzinga
News headline image
FDA Declines To Approve AstraZeneca's Asthma Treatment For Chronic Nasal Condition ↗
The FDA has declined to approve AstraZeneca Plc's (NASDAQ: AZN) asthma medicine, Fasenra (benralizumab), to treat chronic rhinosinusitis with nasal polyps, a... 
Via Benzinga
News headline image
AstraZeneca-Merck's Lynparza Wins FDA Approval For Early-Stage Breast Cancer ↗
The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) cancer drug, jointly developed with Merck & Co Inc (NYSE: MRK) to treat patients with early-... 
Via Benzinga
News headline image
AstraZeneca-Sanofi's Nirsevimab Shows 75% Efficacy Against RSV In Healthy Infants ↗
AstraZeneca Plc (NASDAQ: AZN) and Sanofi SA (NASDAQ: SNY) have shared detailed results from the MELODY Phase 3 trial evaluating nirsevimab in respiratory... 
Via Benzinga
News headline image
AstraZeneca, GSK's COVID-19 Therapies Lose Efficacy Against Omicron's Subvariants ↗
The FDA authorized an increased dose in the case of AstraZeneca Plc's (NASDAQ: AZN) pre-exposure prophylaxis drug Evusheld (tixagevimab and cilgavimab).... 
Via Benzinga
News headline image
Blood Clot Risk After First AstraZeneca COVID-19 Shot Very Small - UK Study Shows ↗
A large study into rare blood clots linked with AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine found between one and three cases per million, and only after... 
Via Benzinga
News headline image
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit ↗
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly... 
Via Benzinga
News headline image
AstraZeneca's Enhertu Meets Primary Endpoint In HER2-Low Breast Cancer Setting ↗
AstraZeneca plc (NASDAQ: AZN) said that Enhertu prolonged survival and slowed the progression of metastatic breast cancer with low levels of a protein known as HER2... 
Via Benzinga
News headline image
GSK Halts Late-Stage RSV Vaccine Trial In Pregnant Women ↗
GlaxoSmithKline plc (NYSE: GSK) has paused a late-stage trial of its respiratory syncytial virus (RSV) vaccine candidate in pregnant women based on safety... 
Via Benzinga
News headline image
Short Shelf Life Of AstraZeneca's COVID-19 Shot Entangles Vaccine Rollout In Poorer Nations: Reuters ↗
According to officials and internal World Health Organization documents reviewed by Reuters, the relatively short shelf life of AstraZeneca Plc's (NASDAQ: AZN)... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.